Ivan Borrello

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5897193/publications.pdf

Version: 2024-02-01

46 papers	8,311 citations	186209 28 h-index	265120 42 g-index
46 all docs	46 docs citations	46 times ranked	11107 citing authors

#	Article	IF	Citations
1	FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology. Blood Advances, 2022, 6, 690-703.	2.5	19
2	Nonmyeloablative Allogeneic Transplantation With Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia With IDH Mutations: A Single Center Experience. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 260-269.	0.2	4
3	Post-Transplantation Cyclophosphamide-Based Graft- versus-Host Disease Prophylaxis with Nonmyeloablative Conditioning for Blood or Marrow Transplantation for Myelofibrosis. Transplantation and Cellular Therapy, 2022, 28, 259.e1-259.e11.	0.6	11
4	Abstract P2-14-07: Marrow-infiltrating lymphocytes as adoptive immunotherapy for breast cancer. Cancer Research, 2022, 82, P2-14-07-P2-14-07.	0.4	0
5	Point of care, bone marrow mononuclear cell therapy in ischemic heart failure patients personalized for cell potency: 12-month feasibility results from CardiAMP heart failure roll-in cohort. International Journal of Cardiology, 2021, 326, 131-138.	0.8	13
6	A randomized, phase II trial of adjuvant immunotherapy with durable TKI-free survival in patients with chronic phase CML. Leukemia Research, 2021, 111, 106737.	0.4	4
7	Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults. Blood Advances, 2020, 4, 3913-3925.	2.5	52
8	Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide. Blood Advances, 2020, 4, 1770-1779.	2.5	92
9	Haploidentical transplantation using posttransplant cyclophosphamide as GVHD prophylaxis in patients over age 70. Blood Advances, 2019, 3, 2608-2616.	2.5	20
10	Development of Grade II Acute Graft-versus-Host Disease Is Associated with Improved Survival after Myeloablative HLA-Matched Bone Marrow Transplantation using Single-Agent Post-Transplant Cyclophosphamide. Biology of Blood and Marrow Transplantation, 2019, 25, 1128-1135.	2.0	38
11	Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 1022-1028.	2.0	29
12	Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide Using Nonâ€“First-Degree Related Donors. Biology of Blood and Marrow Transplantation, 2018, 24, 1099-1102.	2.0	61
13	Grade II Acute Graft-versus-Host Disease and Higher Nucleated Cell Graft Dose Improve Progression-Free Survival after HLA-Haploidentical Transplant with Post-Transplant Cyclophosphamide. Biology of Blood and Marrow Transplantation, 2018, 24, 343-352.	2.0	61
14	Early Fever after Haploidentical Bone Marrow Transplantation Correlates with Class II HLA-Mismatching and Myeloablation but Not Outcomes. Biology of Blood and Marrow Transplantation, 2018, 24, 2056-2064.	2.0	32
15	A phase 1 multicenter study evaluating KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma.. Journal of Clinical Oncology, 2018, 36, TPS3103-TPS3103.	0.8	7
16	Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide. Haematologica, 2017, 102, 391-400.	1.7	152
17	Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide. Blood Advances, 2017, 1, 288-292.	2.5	84
18	Flow cytometric discrimination of seven lineage markers by using two fluorochromes. PLoS ONE, 2017, 12, e0188916.	1.1	4

#	Article	IF	Citations
19	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. , 2016, 4, 90.		17
20	IQGAP1 Scaffoldâ€“MAP Kinase Interactions Enhance Multiple Myeloma Clonogenic Growth and Self-Renewal. Molecular Cancer Therapeutics, 2016, 15, 2733-2739.	1.9	10
21	The immunotherapy era of myeloma: monoclonal antibodies, vaccines, and adoptive T-cell therapies. Blood, 2016, 128, 1679-1687.	0.6	57
22	Persistence of Non Gene-Modified Adoptively Transferred Marrow Infiltrating Lymphocytes (MILs) More Than Five Years Post Transfer. Blood, 2016, 128, 4552-4552.	0.6	1
23	The Incidence of Adrenal Insufficiency in Myeloma Patients Receiving Pulse-Dose Dexamethasone. Blood, 2016, 128, 5640-5640.	0.6	0
24	Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. Blood, 2015, 125, 3024-3031.	0.6	259
25	Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma. Science Translational Medicine, 2015, 7, 288ra78.	5.8	104
26	Pre-radiation lymphocyte harvesting and post-radiation reinfusion in patients with newly diagnosed high grade gliomas. Journal of Neuro-Oncology, 2015, 124, 307-316.	1.4	36
27	Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults. Journal of Clinical Oncology, 2015, 33, 3152-3161.	0.8	215
28	PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma. New England Journal of Medicine, 2015, 372, 311-319.	13.9	3,099
29	Targeting Immune Suppression with PDE5 Inhibition in End-Stage Multiple Myeloma. Cancer Immunology Research, 2014, 2, 725-731.	1.6	99
30	Activation of Liver X Receptors Inhibits Hedgehog Signaling, Clonogenic Growth, and Self-Renewal in Multiple Myeloma. Molecular Cancer Therapeutics, 2014, 13, 1873-1881.	1.9	27
31	Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. Blood, 2014, 124, 3817-3827.	0.6	165
32	Feasibility of lymphocyte harvesting and reinfusion in patients with newly diagnosed high-grade gliomas.. Journal of Clinical Oncology, 2014, 32, 2094-2094.	0.8	2
33	Lenalidomide-Induced Immunomodulation in Multiple Myeloma: Impact on Vaccines and Antitumor Responses. Clinical Cancer Research, 2012, 18, 1426-1434.	3.2	102
34	Can we change the disease biology of multiple myeloma?. Leukemia Research, 2012, 36, S3-S12.	0.4	50
35	Total costs of therapy with lenalidomide or bortezomib in relapsed/refractory multiple myeloma (rrMM).. Journal of Clinical Oncology, 2012, 30, e18561-e18561.	0.8	0
36	The Immune Microenvironment of Myeloma. Cancer Microenvironment, 2011, 4, 313-323.	3.1	44

#	Article	IF	Citations
37	A novel role of IL-17â€“producing lymphocytes in mediating lytic bone disease in multiple myeloma. Blood, 2010, 116, 3554-3563.	0.6	187
38	Nonmyeloablative HLA-Haploidentical Bone Marrow Transplantation with High-Dose Posttransplantation Cyclophosphamide: Effect of HLA Disparity on Outcome. Biology of Blood and Marrow Transplantation, 2010, 16, 482-489.	2.0	260
39	HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide. Biology of Blood and Marrow Transplantation, 2008, 14, 641-650.	2.0	1,525
40	Clonogenic Multiple Myeloma Progenitors, Stem Cell Properties, and Drug Resistance. Cancer Research, 2008, 68, 190-197.	0.4	495
41	Update on Phase I Clinical Trial of IPI-504, a Novel, Water-Soluble Hsp90 Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM).. Blood, 2006, 108, 3579-3579.	0.6	10
42	Activated Marrow-Infiltrating Lymphocytes Effectively Target Plasma Cells and Their Clonogenic Precursors. Cancer Research, 2005, 65, 2026-2034.	0.4	111
43	Cross-presentation of tumor antigens by bone marrowâ€“derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression. Blood, 2001, 98, 1070-1077.	0.6	197
44	Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)â€“producing tumor vaccines. Blood, 2000, 95, 3011-3019.	0.6	159
45	Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)â€“producing tumor vaccines. Blood, 2000, 95, 3011-3019.	0.6	3
46	Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nature Medicine, 1999, 5, 780-787.	15.2	394